Cancer is the leading cause of death in Canada. A promising new way to treat cancer is through the administration of immune cells that target the cancer – an approach called cancer immunotherapy. The goal of this project is to engineer better culture vessels to produce dendritic cells. Dendritic cells are the "gatekeepers" of our immune system. They can have the capacity to activate other immune cells to attack cancers. The project involves two industrial partners: Kanyr Pharma, Inc. and Saint- Gobain, Inc.